Skip to content
Clinical Trials – home

Instituto Hispalense De Pediatria S.L.

Research site

Spain Calle Del Jardin De La Isla Num 6, 41014 Sevilla, Spain

  • 3 trials recruiting
  • Meningococcal immunisation · Beta haemolytic streptococcal infection · Cytomegalovirus immunisation
  • Adults and children

About Specializations

Instituto Hispalense De Pediatria S.L. in Sevilla, Spain specialises in clinical trials of conditions such as Meningococcal immunisation, Beta haemolytic streptococcal infection, Cytomegalovirus immunisation, Group B streptococcus neonatal sepsis, and other specialisations. This site conducts important research.

Main research areas of the site

Musculoskeletal Diseases

At Instituto Hispalense De Pediatria S.L., research in musculoskeletal diseases focuses on knee osteoarthritis pain, with studies designed to assess whether a new therapy can improve pain control and overall treatment effectiveness compared with placebo.

  • Evaluating symptom relief in knee osteoarthritis
  • Testing a potential new treatment for joint pain
  • Measuring effectiveness against placebo

This work reflects a broader interest in finding better options for managing chronic pain and improving quality of life for adults with degenerative joint disease.

Bacterial Infections and Mycoses

The site is actively involved in bacterial infections research, especially studies on meningococcal disease and group B streptococcus, with a strong emphasis on developing and assessing vaccines for prevention.

  • Studying meningococcal infection prevention through vaccination
  • Assessing immune protection against invasive meningococcal disease
  • Evaluating maternal vaccination strategies for group B streptococcus

These trials aim to understand safety, immune response, and the ability of vaccines to reduce serious infections in children, adolescents, pregnant women, and infants.

Virus Diseases

Research in virus diseases includes studies on cytomegalovirus infection and respiratory syncytial virus, with trials focused on preventing infection and lowering the risk of severe respiratory illness.

  • Testing a vaccine to prevent primary cytomegalovirus infection
  • Assessing protection against RSV lower respiratory tract disease
  • Reviewing safety and immune responses in healthy participants

At this Sevilla site, the viral research portfolio centers on vaccine development and on determining whether these approaches can improve protection in vulnerable populations, including infants and women of childbearing age.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle Del Jardin De La Isla Num 641014 SevillaSpain
Recruiting now
3 trials
Conditions studied
19

More sites in SevillaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

14 clinical trials

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
  • Sponsor:Pfizer Inc.

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
  • Sponsor:Pfizer Inc.

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Varicella+5

Not yet recruiting

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Study on the Safety and Immune Response of mRNA-1345 and mRNA-1365 for Infants with Acute Lower Respiratory Infection Aged 5 to 24 Months

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:MRNA-1345
  • Sponsor:Moderna Inc.

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Sanofi Pasteur Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.